Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou C. P. Kuppen*, Hans M. Westgeest, Maarten J. van der Doelen, Alphonsus J. M. van den Eertwegh, Jules L. L. M. Coenen, Katja K. H. Aben, Alphons C. M. van den Bergh, Andries M. Bergman, Joan van den Bosch, Filiz Celik, Mathijs P. Hendriks, Jules Lavalaye, Saskia van der Meer, Marco B. Polee, Diederik M. Somford, Inge M. van Oort, Carin A. Uyl-de Groot, Winald R. Gerritsen

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

15 Citaten (Scopus)
35 Downloads (Pure)


Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p <0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

Originele taal-2English
Pagina's (van-tot)1371-1384
Aantal pagina's14
TijdschriftFuture oncology
Nummer van het tijdschrift19
StatusPublished - jul-2020

Citeer dit